- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
UK First Country to Approve Merck’s COVID-19 Pill
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for Merck and Ridgeback Therapeutics’ molnupiravir (to be trademarked LAGEVRIO in the UK). Results from an interim analysis from the Phase III MOVe-OUT clinical trial showed that the oral treatment could halve the risk of hospitalization or death for adults with a positive SARS-CoV-2 diagnostic test and mild to moderate COVID symptoms and who had at least one risk factor have at least one risk factor for developing severe illness.
The approval is ”a major achievement in Merck’s singular legacy of bringing forward breakthrough medicines and vaccines to address the world’s greatest health challenges,“ said Robert M. Davis, the company’s chief executive officer and president.
Wendy Holman, chief executive officer of Ridgeback Biotherapeutics, commented: ”It is also gratifying to see the first global authorization occur in the UK, the very place where we administered molnupiravir to the first brave human volunteer.”
Fierce Females in the Life Science Space
March 29th 2024In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.
FDA Approves Stelara Biosimilar Selarsdi to Treat Psoriasis, Psoriatic Arthritis
April 17th 2024Alvotech’s and Teva's Selarsdi (ustekinumab-aekn), the second FDA-approved biosimilar to Stelara, is indicated to treat patients aged 6 years and above with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and for patients aged 6 years and above with active psoriatic arthritis.
